Nicholas C. Rohs, MD

Nivolumab plus ipilimumab continued to provide long-term OS benefits compared with chemotherapy as initial treatment for advanced non-small cell lung cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.